MA30602B1 - Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs - Google Patents

Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs

Info

Publication number
MA30602B1
MA30602B1 MA31591A MA31591A MA30602B1 MA 30602 B1 MA30602 B1 MA 30602B1 MA 31591 A MA31591 A MA 31591A MA 31591 A MA31591 A MA 31591A MA 30602 B1 MA30602 B1 MA 30602B1
Authority
MA
Morocco
Prior art keywords
modulators
treatment
metabolism
disorders
present
Prior art date
Application number
MA31591A
Other languages
English (en)
French (fr)
Inventor
Robert M Jones
Juerg Lehmann
Wong Amy Siu-Ting
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA30602B1 publication Critical patent/MA30602B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA31591A 2006-07-06 2009-01-27 Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs MA30602B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81927806P 2006-07-06 2006-07-06

Publications (1)

Publication Number Publication Date
MA30602B1 true MA30602B1 (fr) 2009-07-01

Family

ID=38895258

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31591A MA30602B1 (fr) 2006-07-06 2009-01-27 Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs

Country Status (30)

Country Link
US (1) US20090286816A1 (enExample)
EP (1) EP2051976B1 (enExample)
JP (1) JP2009542699A (enExample)
KR (1) KR20090029781A (enExample)
CN (1) CN101484441A (enExample)
AR (1) AR061968A1 (enExample)
AT (1) ATE469145T1 (enExample)
AU (1) AU2007269571A1 (enExample)
BR (1) BRPI0713998A2 (enExample)
CA (1) CA2656623A1 (enExample)
CL (1) CL2007001971A1 (enExample)
CO (1) CO6160319A2 (enExample)
CR (1) CR10537A (enExample)
DE (1) DE602007006815D1 (enExample)
DK (1) DK2051976T3 (enExample)
EA (1) EA200970088A1 (enExample)
EC (1) ECSP099037A (enExample)
ES (1) ES2344965T3 (enExample)
GT (1) GT200800306A (enExample)
IL (1) IL195851A0 (enExample)
MA (1) MA30602B1 (enExample)
MX (1) MX2008016253A (enExample)
NO (1) NO20090591L (enExample)
PE (1) PE20080519A1 (enExample)
SV (1) SV2009003146A (enExample)
TN (1) TNSN08533A1 (enExample)
TW (1) TW200811147A (enExample)
UY (1) UY30467A1 (enExample)
WO (1) WO2008005569A2 (enExample)
ZA (1) ZA200900055B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
JP2012502081A (ja) * 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
JP5657518B2 (ja) 2009-02-18 2015-01-21 武田薬品工業株式会社 縮合複素環化合物
WO2010135506A1 (en) * 2009-05-20 2010-11-25 Janssen Pharmaceutica Nv Process for the preparation of 4- [6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino) -5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
EA201200046A1 (ru) 2009-06-24 2012-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения, фармацевтическая композиция и связанные с ними способы
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011094008A1 (en) 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9000175B2 (en) 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
EA031618B1 (ru) 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Соединения-модуляторы gpr-119
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2771151T3 (es) 2013-07-29 2020-07-06 Kyowa Hakko Kirin Co Ltd Derivados de piperidina como inhibidor de señalización wnt
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN104003942A (zh) * 2014-03-10 2014-08-27 常熟市南湖实业化工有限公司 避免串温现象产生的5-甲氧基-4,6-二氯嘧啶制备方法
EP3242666B9 (en) 2015-01-06 2024-12-25 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
CN105111151B (zh) * 2015-04-17 2018-09-28 成都理工大学 作为PPAR-γ调节剂的氨基嘧啶衍生物
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN108658871B (zh) * 2018-06-19 2020-10-30 舞阳威森生物医药有限公司 周效磺胺中间体4,6-二氯-5-甲氧基嘧啶的制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH499528A (de) * 1965-10-22 1970-11-30 Ciba Geigy Ag Verfahren zur Herstellung neuer Pyrimidine
CH480410A (de) * 1967-01-09 1969-10-31 Geigy Ag J R Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en) * 1967-01-12 1975-01-14 Max Schellenbaum N-2-ethylhexyl-n'-aryl ureas and preparation containing them
US3608087A (en) * 1968-06-21 1971-09-21 Merck & Co Inc Feed compositions
US3887329A (en) * 1969-05-05 1975-06-03 Ciba Geigy Ag Hexamethyl phosphotriamide-dye compositions
US3686238A (en) * 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en) * 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3966744A (en) * 1971-01-11 1976-06-29 Syva Company Spin labeled compounds
US3690834A (en) * 1971-01-11 1972-09-12 Syva Co Ligand determination with spin labeled compounds by receptor displacement
DE2106585A1 (de) * 1971-02-11 1972-08-24 Farbenfabriken Bayer Ag, 5090 Leverkusen Aminothiodiazole und Thiodiazol-Azofarbstoffe
US3966764A (en) * 1972-07-10 1976-06-29 Syva Company Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en) * 1972-10-20 1974-11-19 Dow Chemical Co Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (enExample) * 1972-11-16 1976-04-15 Ciba Geigy Ag
DE2340569C2 (de) * 1973-08-10 1982-12-02 Bayer Ag, 5090 Leverkusen Azofarbstoffe
AT340933B (de) * 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
US4101541A (en) * 1973-12-21 1978-07-18 Ciba-Geigy Corporation 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
FR2306697A1 (fr) * 1975-04-10 1976-11-05 Sogeras Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
DE2731264A1 (de) * 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja) * 1977-12-09 1985-09-02 コニカ株式会社 ハロゲン化銀カラ−写真感光材料
US4242507A (en) * 1978-02-23 1980-12-30 Fujisawa Pharmaceutical Co., Ltd. Sulfonic acid esters
DE2831580C2 (de) * 1978-07-18 1980-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung von Glycerin
DE2906603A1 (de) * 1979-02-21 1980-09-04 Boehringer Mannheim Gmbh N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
DOP1981004033A (es) * 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
DE3334455A1 (de) * 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3601196A1 (de) * 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
US5364865A (en) * 1992-12-30 1994-11-15 Sterling Winthrop Inc. Phenoxy- and phenoxyalkyl-piperidines as antiviral agents
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
PT781766E (pt) * 1994-09-09 2004-07-30 Nippon Shinyaku Co Ltd Derivado heterociclico e medicamento
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US6956047B1 (en) * 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6008234A (en) * 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6239126B1 (en) * 1998-12-17 2001-05-29 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6525064B1 (en) * 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
CN102558155A (zh) * 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
EP1606282B1 (en) * 2003-02-24 2008-11-12 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpipereidinye-derivatives as modulators of glucose metabolism
US7083933B1 (en) * 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005007658A2 (en) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
DK1756084T3 (da) * 2004-06-04 2009-03-23 Arena Pharm Inc Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Also Published As

Publication number Publication date
JP2009542699A (ja) 2009-12-03
GT200800306A (es) 2009-04-20
BRPI0713998A2 (pt) 2012-11-20
TW200811147A (en) 2008-03-01
EA200970088A1 (ru) 2009-06-30
WO2008005569A3 (en) 2008-04-10
IL195851A0 (en) 2009-09-01
SV2009003146A (es) 2009-11-04
ECSP099037A (es) 2009-02-27
ES2344965T3 (es) 2010-09-10
CN101484441A (zh) 2009-07-15
ATE469145T1 (de) 2010-06-15
AU2007269571A1 (en) 2008-01-10
KR20090029781A (ko) 2009-03-23
TNSN08533A1 (en) 2010-04-14
CR10537A (es) 2009-01-27
ZA200900055B (en) 2009-12-30
UY30467A1 (es) 2008-02-29
US20090286816A1 (en) 2009-11-19
CL2007001971A1 (es) 2008-01-25
CO6160319A2 (es) 2010-05-20
AR061968A1 (es) 2008-08-10
HK1128921A1 (en) 2009-11-13
CA2656623A1 (en) 2008-01-10
EP2051976B1 (en) 2010-05-26
NO20090591L (no) 2009-02-06
PE20080519A1 (es) 2008-05-16
MX2008016253A (es) 2009-02-25
EP2051976A2 (en) 2009-04-29
DE602007006815D1 (de) 2010-07-08
WO2008005569A2 (en) 2008-01-10
DK2051976T3 (da) 2010-09-20

Similar Documents

Publication Publication Date Title
MA30602B1 (fr) Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs
MA30601B1 (fr) Modulateurs de metabolisme et traitement de troubles metaboliques
MA29860B1 (fr) Modulateurs du metabolisme et le traitement de troubles s'y rapportant
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA29795B1 (fr) Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA29387B1 (fr) Inhibiteurs de la dipeptidyl peptidase iv
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA30686B1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase.
MA29731B1 (fr) Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
MA29909B1 (fr) Derives de pyridazine
MY164646A (en) Nicotine lozenge compositions
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
MA28437B1 (fr) Composes et leurs procedes d'utilisation
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
TN2009000028A1 (fr) Agonistes de ep2